Abid Khokar, MD
Pulmonary Disease · Phoenix, AZNPI 1265702856
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (50.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 89.9% of it on its own, with 28 other manufacturers making up the rest. 2025 is the largest year on record at $103,828, more than ten times the $665 reported in 2019. Among pulmonary disease clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 449 payments — averaging $584.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$236K
- Serpex Medical Inc$16K
- Pinnacle Biologics, Inc$4K
- Merit Medical Systems Inc$2K
- Pulmonx Corporation$1K
- Olympus America Inc.$1K
- plus $2K from 23 others
Across 8 payments — averaging $7300.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Serpex Medical Inc$30K
- Gyrus ACMI, Inc.$29K
What the payments were for
- Consulting fees$16,9686%
- Speaking & faculty fees$68,92526%
- Travel & lodging$24,7409%
- Food & beverage$18,1777%
- Education$133,50051%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 309 | $235,878 |
| Serpex Medical Inc | 4 | $16,106 |
| Pinnacle Biologics, Inc | 6 | $3,633 |
| Merit Medical Systems Inc | 11 | $1,801 |
| Pulmonx Corporation | 12 | $1,339 |
| Olympus America Inc. | 53 | $1,233 |
| Olympus Corporation Of The Americas | 1 | $300 |
| Fisher & Paykel Healthcare Inc | 1 | $263 |
| AbbVie(2 entities) | 2 | $247 |
| Johnson & Johnson(2 entities) | 3 | $175 |
| Inari Medical, Inc. | 1 | $173 |
| Philips North America LLC | 8 | $166 |
| GSK | 11 | $155 |
| Sanofi | 1 | $141 |
| Merck | 1 | $114 |
| AstraZeneca | 6 | $111 |
| Imbio Inc. | 1 | $90 |
| Boehringer Ingelheim | 3 | $65 |
| Actelion Pharmaceuticals US, Inc. | 2 | $48 |
| United Therapeutics Corporation | 2 | $47 |
| Medical Device Business Services, Inc. | 1 | $33 |
| Pharmacosmos Therapeutics Inc. | 1 | $33 |
| Electromed, Inc. | 2 | $28 |
| Sunovion Pharmaceuticals Inc. | 2 | $28 |
| Polarean, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Shionogi Inc | 1 | $20 |
| Insmed, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$215,959
- DA VINCI SP$16,150
- Photofrin$3,565
- FISHER & PAYKEL HEALTHCARE$1,317
- ZEPHYR ENDOBRONCHIAL VALVE$1,107
- Spiration Valve System$801
- CHARTIS CATHETER$707
- ZEPHYR DELIVERY CATHETER$707
- PULMONX CHARTIS TABLET CONSOLE$707
- AEROflex$700
- Cryo BX$350
- CryoBX$350
- MAXXWIRE$350
- Through The Scope$350
- AVYCAZ$247
- FLOWTRIEVER CATHETER, S$173
- CT THROMBECTOMY SYSTEM KIT$173
- DUPIXENT$141
- Always-On Tip Tracked Forceps, 1.8mm OD, Serrated Cup$122
- Monarch Platform$121
How this compares
$262,309 in reported general payments places this provider in the 95th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $6,924 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKAnoro Ellipta | $155 | $6,92412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Phoenix
- Rajat WaliaPhoenix$748K
- Brian PorvinPhoenix$276K
- Tony HodgesPhoenix$248K
- Mark GotfriedPhoenix$196K
- Rajeev SaggarPhoenix$161K
- Gregory AhearnPhoenix$144K
- Jagruti PatelPhoenix$141K
- Ali SaeedPhoenix$138K
- Ramit SharmaPhoenix$65K
- Bhuvin BuddhdevPhoenix$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.